ANDA 202740, held by Xiromed. Levonorgestrel.
As of Nov 13, 2026, ANDA 202740 (Levonorgestrel), held by Xiromed, was first approved by FDA on Sep 2, 2016, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 2, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levonorgestrel0.75MG ยท tablet;oral | Levonorgestrel | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
